Joint (NASDAQ:JYNT) Stock Rating Lowered by Zacks Investment Research

Zacks Investment Research cut shares of Joint (NASDAQ:JYNT) from a buy rating to a hold rating in a research note released on Saturday morning, Zacks.com reports.

According to Zacks, “The Joint Corp. is a healthcare franchisor of chiropractic clinics. The Company’s plans include: Single Visit, Premium Wellness Plan and Wellness Plan. It also provides a family wellness plan. The Company also provides removal of subluxations. It operates its clinics across: Albany, New York; Austin, Texas; Brentwood, California; Fort Mill, South Carolina; Lubbock, Texas; Lynnwood, Washington; Middletown, New Jersey; San Antonio, Texas; San Diego, California and Spartanburg, South Carolina, among others. The Joint Corp. is headquartered in Scottsdale, Arizona. “

JYNT has been the subject of several other research reports. Maxim Group reaffirmed a buy rating and set a $25.00 price objective on shares of Joint in a report on Friday, August 9th. BidaskClub raised shares of Joint from a buy rating to a strong-buy rating in a report on Thursday, September 19th. ValuEngine lowered shares of Joint from a buy rating to a hold rating in a report on Wednesday, October 2nd. Lake Street Capital raised their price objective on shares of Joint from $20.00 to $30.00 and gave the stock a buy rating in a report on Friday, August 9th. Finally, TheStreet lowered shares of Joint from a b- rating to a c rating in a report on Tuesday, September 3rd. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. Joint presently has an average rating of Buy and an average target price of $23.67.

NASDAQ:JYNT opened at $19.64 on Friday. Joint has a 12-month low of $6.51 and a 12-month high of $21.80. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 3.33. The firm has a market capitalization of $265.87 million, a PE ratio of 491.00 and a beta of 1.02. The firm has a 50-day moving average price of $18.19 and a 200 day moving average price of $17.84.

Joint (NASDAQ:JYNT) last posted its quarterly earnings results on Thursday, August 8th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.02 by $0.01. The firm had revenue of $11.17 million during the quarter, compared to analyst estimates of $11.08 million. Joint had a net margin of 5.38% and a return on equity of 114.93%. On average, research analysts expect that Joint will post 0.2 EPS for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of JYNT. Tower Research Capital LLC TRC boosted its position in shares of Joint by 1,199.3% during the second quarter. Tower Research Capital LLC TRC now owns 1,767 shares of the company’s stock worth $32,000 after purchasing an additional 1,631 shares in the last quarter. Winslow Evans & Crocker Inc. bought a new stake in Joint in the 3rd quarter valued at $36,000. Marshall Wace North America L.P. bought a new stake in Joint in the 1st quarter valued at $47,000. Strs Ohio bought a new stake in Joint in the 2nd quarter valued at $63,000. Finally, Russell Investments Group Ltd. bought a new stake in Joint in the 2nd quarter valued at $71,000. 62.76% of the stock is owned by institutional investors.

Joint Company Profile

The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics. The company operates through two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising, and the sale of regional developer rights. As of March 07, 2019, the company operated 450 clinics in the United States.

See Also: Exchange-Traded Funds (ETFs)

Get a free copy of the Zacks research report on Joint (JYNT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Joint (NASDAQ:JYNT)

Receive News & Ratings for Joint Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Joint and related companies with MarketBeat.com's FREE daily email newsletter.